Opko Health (OPK)Director bought ~$11K

~$11K

Approx. value · 10K sh @ $1.14

394K

Holds after · shares reported

Traded

Mar 20, 2026

Filed

Mar 20, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Feb 26, 2026Company filing · Form 8-K · ResultsReported its results
2. Mar 18, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 18, 2026, the Board of Directors of OPKO Health, Inc. (the “Company”), appointed Subbarao V. Uppaluri, Ph.D. as a new director with immediate effect to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor shall be duly elected or appointed or his earlier death or resignation.”
3. Mar 20, 2026 · this disclosureInsider · First buy since 2024Director purchased ~$11K of OPK shares in the open market

What came next

1. Apr 28, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Opko Health

OQRO holds no insider, Congress, fund or contract record for Opko Health dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its OPK page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Opko Health

• SEC Form 4Nov 21, 2025
• SEC Form 4Nov 21, 2025
• SEC Form 4Nov 21, 2025
• SEC Form 4Nov 21, 2025
• SEC Form 4Nov 21, 2025
• SEC Form 4Nov 20, 2025

Everything OQRO holds on this company is on its OPK page.